Attainment of individual MDA components in MDA achievers and non-achievers at week 24 by randomised treatment
| MDA component | MDA achievers | MDA non-achievers | ||||
| Patients meeting criterion, n (%) | Response difference (95% CI) | Patients meeting criterion, n (%) | Response difference (95% CI) | |||
| Adalimumab (n=24) | Placebo (n=4) | Adalimumab (n=37) | Placebo (n=55) | |||
| TJC≤1 | 20 (83.3) | 3 (75.0) | 8.3 (–36.6 to 53.3) | 4 (10.8) | 3 (5.5) | 5.4 (–6.3 to 17.0) |
| SJC≤1 | 14 (58.3) | 2 (50.0) | 8.3 (–44.9 to 61.2) | 5 (13.5) | 6 (10.9) | 2.6 (–11.2 to 16.4) |
| PASI≤1 | 21 (87.5) | 0 | 87.5 (74.3 to 100)* | 15 (40.5) | 2 (3.6) | 36.9 (20.3 to 53.5)** |
| Patient pain ≤15 | 24 (100) | 4 (100) | 0 | 6 (16.2) | 3 (5.5) | 10.8 (–2.6 to 24.1) |
| PtGA≤20 | 24 (100) | 4 (100) | 0 | 6 (16.2) | 7 (12.7) | 3.5 (–11.3 to 18.3) |
| HAQ-DI≤0.5 | 23 (95.8) | 4 (100) | –4.2 (–12.2 to 3.8) | 8 (21.6) | 17 (30.9) | –9.3 (–27.3 to 8.7) |
| Tender entheseal points ≤1 | 24 (100) | 4 (100) | 0 | 26 (70.3) | 35 (63.6) | 6.6 (–12.8 to 26.1) |
**p<0.001; *p<0.01.
HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PtGA, Patient Global Assessment of disease activity; SJC, swollen joint count of 76 joints; TJC, tender joint count of 78 joints.